

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over ID6579


Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
Johnson & Johnson (icotrokinra)	All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
Changing Faces	Board of Community Health Councils in Walsa
Genetic Alliance UK Gara Basala	Wales
Gene People Let's Face It	British National Formulary Care Overlity Commissions
Let's Face It Pagination of Description Authorities	Care Quality Commission Department of the aller Martiness Includes
Psoriasis and Psoriatic Arthritis Alliance (PARAA)	Department of Health - Northern Ireland Lighthage Improvement Sections
Alliance (PAPAA)	Healthcare Improvement Scotland Madicines and Use Illustrations
Psoriasis Association Psoriasis Usin Organization	Medicines and Healthcare products Pagulatany Aganay
Psoriasis Help Organisation South Asian Health Foundation	Regulatory Agency
South Asian Health Foundation	National Association of Primary Care
Specialised Healthcare Alliance	National Pharmacy Association
1144	NHS Confederation
Healthcare professional groups	NHS Wales Joint Commissioning
Association of Genetic Nurses & Coupagliars	Committee
Counsellors	Scottish Medicines Consortium
British Association of Dermatologists	Welsh Government
British Dermatological Nursing Group Dritish Cariatrias Casiatri	Danikla annonantan annonania
British Geriatrics Society Delitish Geriatrics Society	Possible comparator companies
British Society for Cutaneous Allergy	AbbVie (adalimumab, risankizumab)
British Society for Genetic Medicine	Almirall (dimethyl fumarate,
Primary Care Dermatology Society	tildrakizumab)
Royal College of General PractitionersRoyal College of Nursing	 Amgen (adalimumab, apremilast, ustekinumab)
Royal College of Pathologists	Aspire Pharma (dimethyl fumarate)
Royal College of Physicians	Biogen Idec (adalimumab, dimethyl
Royal Pharmaceutical Society	fumarate, etanercept, infliximab)
Royal Society of Medicine	Bristol Myers Squibb (deucravacitinib)
St John's Institute of Dermatology	Celix Pharma (dimethyl fumarate)
UK Clinical Pharmacy Association	Celltrion Healthcare (adalimumab, infliximab, ustekinumab)
Othoro	Cipla (methotrexate)
Others	
Department of Health and Social Care NUC Frederick	
NHS England	 Ell Lilly and Company (Ixekizumab) Esteve Pharmaceuticals (methotrexate)

Provisional stakeholder list for the evaluation of icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over ID6579



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
	Fresenius Kabi (adalimumab, ustekinumab) Genus Pharmaceuticals (acitretin, dimethyl fumarate, ustekinumab) Hospira (methotrexate) Janssen-Cilag (guselkumab, infliximab, ustekinumab) Leo Pharma (brodalumab) Medac (methotrexate) Morningside Healthcare (acitretin, ciclosporin, methotrexate) MSN Laboratories (dimethyl fumarate) Mylan (ciclosporin, dimethyl fumarate) Nordic Pharma (methotrexate) Novartis Pharmaceuticals UK (ciclosporin, secukinumab) Orion Pharma (methotrexate) Pfizer (etanercept, infliximab, Rosemont Pharmaceuticals (methotrexate) Samsung Bioepis (Ustekinumab) Santen (ciclosporin) Sandoz (adalimumab, etanercept, infliximab, methotrexate) Sun Pharma (ciclosporin) Teva UK (acitretin, UCB Pharma (bimekizumab, certolizumab pegol) Wockhardt UK (dimethyl fumarate)
	 Relevant research groups British Skin Foundation Centre of Evidence-based Dermatology, University of Nottingham Cochrane Skin Group Genomics England MRC Clinical Trials Unit National Institute for Health Research
	Associated Public Health groupsPublic Health WalesUK Health Security Agency



NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.